Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept trial of siponimod (BAF312) in polymyositis
2012-002859-42Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in polymyositis (PM) comparing Siponimod 2 mg once daily with Placebo (2 arms). Primary endpoint: manual muscle testing (MMT-8) and serum creatine kinase levels. Started Nov 2012; status: completed.
02
Drugs
siponimod
03
Conditions
polymyositis (PM)
Beyond the preview
Go deeper on 2012-002859-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002859-42.